BHC
Bausch Health Companies Inc
Healthcare
06/27/2014
Presented
| Date | 06/24/2014 |
| Price | $129.41 |
| Market Cap | $43.40B |
| Ent Value | $62.03B |
| P/E Ratio | 76.39x |
| Book Value | $15.89 |
| Div Yield | N/A |
| Shares O/S | 335.27M |
| Ave Daily Vol | 400,000 |
| Short Int | N/A |
Current
| Price | $8.39 |
| Market Cap | $3.08B |
| Bausch Health Companies Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada. |
Please note, on 7/16/18 Valeant Pharmaceuticals International Inc (VRX) changed it’s company name and ticker to Bausch Health Companies Inc. (BHC). The content of this idea will make reference to the original company name and ticker symbol.
Publicly traded companies mentioned herein: Allergan (AGN), Valeant Pharmaceuticals International, Inc. (VRX)
Highlights
Shares of Valeant Pharmaceuticals (VRX) have fallen from recent highs ($145-150) to the $120s and the presenter thinks this “broken deal price” has created an attractive entry point (and risk/ reward) for owning the stock. He is long and sees multiple ways to win, including getting the Allergan deal done His opinion is that VRX and Ackman will find a way to close on Allergan, but even if they are unsuccessful the stock is cheap and further downside risk should be limited.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.